Kazia Therapeutics Limited (KZIA)
KZIA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-06-30, https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/0001193125-25-272284-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | KZIA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001075880 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $28K |
| Net income | -$14.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -49290.5% |
| Operating margin | Operating income not reported |
| Revenue growth | -98.2% |
| Cash | $2.9M |
| Total assets | $4.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3055.4× |
Reported in AUD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "There is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements for the fiscal year ended 30 June 2025 are issued." | 20-F 2025-11-07 |
| Cash and burn | 4.3M AUD cash; operating cash flow -3.3M AUD a quarter. | Report 2025-06-30 |
| Shares outstanding | No cover-page share count in XBRL | None on EDGAR |
| Reverse splits, 3 years | 2; latest 1-for-5 on 2025-04-17 | Source 2025-04-17 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 2 at the market | Latest 2026-08-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO Audit Pty Ltd, Sydney, Australia | PCAOB Form AP 2025-11-12 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-11-02 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-06-30 | 42K AUD | -20.7M AUD | -13.3M AUD | 4.3M AUD | 396K AUD | 42K AUD | 20-F 2025-11-07 |
| FY 2024 2024-06-30 | 2.3M AUD | -26.8M AUD | -9.6M AUD | 1.7M AUD | 634K AUD | 2.3M AUD | 20-F 2025-11-07 |
| FY 2023 2023-06-30 | 0 AUD | -20.5M AUD | -15.2M AUD | 5.2M AUD | 1.8M AUD | 0 AUD | 20-F 2025-11-07 |
| FY 2022 2022-06-30 | 0 AUD | -25.0M AUD | -22.8M AUD | 7.4M AUD | 1.8M AUD | 0 AUD | 20-F 2024-11-15 |
| FY 2021 2021-06-30 | 15.2M AUD | -8.4M AUD | -9.1M AUD | 27.6M AUD | 0 AUD | 15.2M AUD | 20-F 2023-10-26 |
| FY 2020 2020-06-30 | Not filed | -12.5M AUD | -8.8M AUD | 8.8M AUD | No debt tags | Needs four quarters | 20-F 2022-10-17 |
| FY 2019 2019-06-30 | Not filed | -10.3M AUD | -6.7M AUD | 5.4M AUD | No debt tags | Needs four quarters | 20-F 2021-10-07 |
| FY 2018 2018-06-30 | 119K AUD | -6.0M AUD | -8.7M AUD | 6.0M AUD | No debt tags | 119K AUD | 20-F 2019-10-21 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in AUD.
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.8% |
| 1 month | -17.7% |
| 3 months | -49.9% |
| Year to date | -3.9% |
| 1 year | -9.2% |
| From 52-week high | -60.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GNLX | Genelux Corporation | $1.92 | +2.95% | $86.9M |
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| RLYB | Rallybio Corporation | $15.43 | -1.88% | $86.4M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
| PLYX | Polaryx Therapeutics Inc. | $1.67 | -6.99% | $83.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier